clinically diagnosed and were culture-positive for ESBLproducing E. coli either from blood, urine, or pus. Standard microbiological methods were used to detect ESBL from clinical and gut isolates. Genes coding for major betalactamase enzymes such as blaCTX-M, blaTEM, and blaSHV were investigated by polymerase chain reaction (PCR).
Background
Extended spectrum betalactamase (ESBL)-producing organisms are a major cause of hospital-acquired infections. The ESBLs are betalactamases, which confer bacterial resistance to penicillin, the first-, second-, and thirdgeneration cephalosporins, and aztreonam (but not the cephamycins and carbapenem) by hydrolysis of these antibiotics. 1 These organisms are inhibited by betalactamase inhibitors like clavulanic acid and tazobactam.
Since its detection in 1983, various organisms have been known to produce these hydrolysing enzymes worldwide among which E.coli is the most common ESBL-producing organism. 1, 2 They are known to cause outbreaks of lifethreatening infections in hospitalised patients. 2 The common risk factors for acquiring infection with ESBLproducing organisms are exposure to prolonged antibiotic therapy, invasive procedures, intra-abdominal surgery, and prolonged hospital stay. 3, 4 The patient's own microflora is thought to be a major contributing factor in advancing the infection. 5 Faecal colonisation of ESBL-producing organisms among healthy individuals in the community is reported to be around 5.5-8 per cent, while colonisation among hospitalised patients was found to be higher; i.e., around 15 per cent. 5 However, colonisation studies on patients who have already been infected with an ESBL-producing strain are limited. The present study was undertaken to detect the presence of some common betalactamase genes in E.coli that are isolated from the gut of patients who had recently been infected with the same organism.
Method
A prospective one-year study was conducted during 2010 in a tertiary care hospital. Non-repetitive faecal samples were collected from 70 in-patients who had laboratory-confirmed infection with an ESBL-producing E.coli cultured from their blood, urine, or pus. The study was approved by the Institutional Ethical Review Committee and an informed consent was obtained from all the participants.
Definitions
The following definitions are used:
Clinical isolate: An isolate from an active site of infection confirmed by culture.
Gut isolate: An isolate from the faeces of a patient who has an active infection with ESBL-producing E. coli and who does not have diarrhoea/dysentery.
In brief, stool culture was performed with a loopful of the faeces sample inoculated onto a MacConkey agar (HiMedia, Mumbai, India) incorporated with ceftazidime [MacConkey agar was prepared by the addition of ceftazidime (2µ g/ml) to the cooled agar before pouring]. 6 After overnight incubation at 37⁰C, 5-6 lactose-fermenting colonies were picked up for further processing. All the gut and clinical isolates were tested for their antibiotic susceptibility pattern according to the CLSI guidelines (CLSI, 2010). 7 All the isolates were also screened for ESBL production (a zone size of ≤27mm for cefotaxime and ceftazidime ≤22mm were considered positive for ESBL production). Isolates were further confirmed as ESBL producers by the double disk diffusion method (CLSI 2010). 7 Ceftazidime (30μg) disk with and without clavulanic acid (30μg/10μg) were used. A ≥5mm increase in the zone diameter for ceftazidime with clavulanic acid was considered positive for ESBL. 7 Reference strains such as Escherichia coli ATCC 25922 and Klebsiella pneumoniae ATCC 700603 were used as a negative and positive control, respectively.
PCR was performed on all the 15 clinical and gut isolates to detect blaCTX-M, blaTEM, and blaSHV genes using specific primers and PCR conditions as described earlier. 8 Primer sequences
and their product sizes are given in Table 1 . 8 PCR reactions
were carried out individually for detection of each of the genes. Briefly, the amplification was carried out in an Eppendorf thermal cycler (Eppendorf, Germany) with the following conditions: (1) Initial denaturation step for five minutes at 94˚C; (2) 35 cycles of PCR were carried out with each cycle consisting of one minute at 94˚C, 1 min at 54˚C, and two minutes at 72˚C; and (3) a final extension step was performed for five minutes at 72˚C. The PCR products were electrophoresed on one per cent agarose gel, stained with ethidium bromide and the bands were visualised under UV illumination (Bio-Rad, USA) ( Figure 1 ).
The comparative study of risk factors among colonisers and non-colonisers were statistically tested using Chi-square or Fisher's Exact Test. A p value of <0.05 was considered statistically significant. Statistical analysis was performed using SPSS software.
Results
Out of the 70 stool samples tested, 15 (21 per cent) patients were found to be colonised with ESBL-producing E.coli in their gut. Out of the 15 colonised patients most (93 per cent) of them were adults and less than half (six patients) were admitted to the intensive care unit during the course of their hospital stay. Of these, 11 had urinary tract infection with an ESBL-producing E.coli, while two patients had blood stream infections, and two others had suppurative infections. In four patients, infection followed surgical procedures like hernioplasty, sigmoid colostomy, kwiring, and abdominal hysterectomy. Central venous catheters were inserted in four patients, while 10 had urinary catheters.
All ESBL-producing E.coli isolated from the gut microflora and the clinical isolates were sensitive to imipenem and amikacin, while gentamicin resistance was seen in 10 (66 per cent), ciprofloxacin in 14 (93 per cent), and meropenem in three (20 per 
Detection of betalactamase genes among gut and clinical isolates
Out of the 15 gut and clinical isolates, the blaCTX-M was found in 13 (86.6 per cent) isolates, and the blaTEM was present in 11 (73.3 per cent) isolates. The blaSHV types were present in eight (53.3 per cent) isolates. Two or more genes were present in 12 (80 per cent) of the stool isolates, the commonest combination was the presence of all three genes (blaTEM, blaCTX-M, and blaSHV types), which was present in six (40 per cent) gut isolates, followed by combination of blaTEM + blaCTX-M in four (26.6 percent), and blaSHV + blaCTX-M in one (6.6 per cent) isolate. Only two of the isolates had a single gene, one had blaCTX-M and the other had blaTEM ( Table  2 ).
The presence of blaCTX-M, blaTEM, and blaSHV genes in the gut isolates were of similar pattern as in clinical isolates in eight patients whose guts were colonised with ESBL strains (Table  3) .
Discussion
ESBL-producing organisms are presently one of the major causes of hospital-acquired infections. 9 Worldwide, the prevalence of ESBL production among E.coli isolates in a hospital setting was highest in Latin America (13.5 per cent), followed by Asia/Pacific Rim (12per cent), Europe (7.6 per cent), and North America (2.2 per cent). 10 The prevalence of ESBL-producing gram-negative isolates in India is alarmingly high (19-69 per cent). [11] [12] [13] In various studies conducted across India the prevalence rate of ESBL-producing E.coli was found to be 41-62 per cent. [14] [15] [16] There is general consensus that gut colonisation in patients by these bacteria is an important reservoir and source of infection. 17 Valverde et al. had reported that the rate of faecal carriage of ESBL-producing Enterobacteriaceae had increased significantly in hospitalised and outpatients from 0.3 and 0.7 per cent, respectively, in 1991, to 11.8 and 5.5
per cent, respectively, in 2003. 18 Faecal carriage rates of ESBL-producing E.coli among children and women attending antenatal clinics in India was found to be 9 per cent and 15
per cent, respectively. 19, 20 There are several reports on the prevalence of faecal carriage of ESBL-producing organisms in both inpatients and outpatients ranging from 5.5-17 percent. [21] [22] [23] Interestingly, the present study witnessed a higher percentage of colonisation (21 per cent) and this could be due to an already existing infection with an ESBLproducing E.coli. All the previous studies on gut microflora were done on either inpatients or outpatients randomly without evidence of an infection.
18-24
Several studies have already revealed various risk factors associated with colonisation and infection with ESBLproducing organisms. Prolonged hospital stay, patients on medical devices like urinary catheters, central venous lines, etc., have been associated with infections by these organisms. 25, 26 Further, surgical procedures and indiscriminate use of antibiotics are added risk factors for the acquisition of ESBL-producing organisms. [27] [28] [29] [30] In this study a major risk factor for colonisation with ESBL producers appears to be invasive devices like urinary catheterisation (p value=0.04). The majority of the colonised patients (73 per cent) in the present study had urinary tract infection with ESBL-producing E. coli, which probably explains the association (Table 4) . Although all the colonisers (100 per cent) were on antibiotic therapy, it did not appear to be a significant risk factor statistically since the number of colonisers were minimal (15 patients), however, antibiotic usage may act as a risk factor, as the antibiotic pressure is high in healthcare facilities.
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With a limited choice of antibiotics, ESBL-producing isolates are reported to be susceptible to imipenem and meropenem, but resistant to a panel of antibiotics, including gentamicin, amikacin, and ciprofloxacin. [31] [32] [33] Resistance pattern of E.coli isolated from the gut microflora in the present study is quite alarming as 46 per cent of isolates were resistant to the betalactamase inhibitors (cefaperazone + sulbactam) and (piperacillin + tazobactam).
As normal microflora of the gut, these organisms could be a threat to the patients who have been colonised, and to the patients who are in the vicinity. This could also pose a challenge to hospital infection control practices.
The antibiogram of the gut isolates had identical susceptibility patterns in comparison to the clinical isolates of the same patient, even though antibiogram typing is a crude method it reiterates an association. However, prior isolation from the gut and a follow-up to see if these patients developed infection subsequently could be a better analytical tool. Molecular typing using multilocus sequence typing (MLST) or pulse-field gel electrophoresis (PFGE) to determine the clonal relatedness of the isolates could have been a better tool to validate such observation. Not performing any of these methods is a limitation of our study.
Earlier studies on genotypic detection of ESBL-producing E. coli from the gut have shown CTX-M as the most common type with 75 per cent of the isolates followed by SHV (20 per cent). 33, 34 In the present study, CTX-M was found in 86 per cent (n=13), the TEM variety in 73 per cent (n=11) of gut isolates. The SHV type was present in only 53.3 per cent (n=8) of isolates. Sequencing of the blaTEM, and blaSHV genes were not performed to confirm it as ESBL genes. However, the presence blaCTX-M gene and the confirmation of all the isolates by phenotypic methods (disk diffusion) deem them as ESBL strains. The presence of one or more resistant genes in a normal coliform suggests that these strains could be a potential threat for causing a future infection elsewhere in the body.
Conclusion
Acquisition with an ESBL-producing organism might be due to dissemination of these resistant strains in the hospital environment, leading to transmission from a common source and/or person-to-person transmission. 35 Our data suggest that colonisation with ESBL-producing organisms could be due to an active infection with an ESBL-producing E. coli. However, specific typing methods are required to support this evidence. The endogenous microflora of colonised patients could act as a reservoir for a future infection with a drug-resistant organism. Therefore, it is prudent to suggest that as a routine, patients admitted to critical care areas such as ICUs, may be screened for colonisation with ESBL-producing organisms. Strict adherence to patient hygiene and infection control practices may be enforced to curtail hospital-acquired infections. Rationalising antibiotic therapy would substantially decrease pressure on the gut microflora and thereby limit acquisition of resistance genes among these organisms.
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